H.C. Wainwright analyst Sean Lee raised the firm’s price target on Plus Therapeutics to $8 from $3.50 and keeps a Buy rating on the shares. The company announced positive updates from the Phase 1/2 ReSPECT-GBM study and the Phase 1 ReSPECT-LM study, the analyst tells investors in a research note. The firm says the results continue to highlight rhenium obisbemeda as a promising therapy for the treatment of recurrent glioblastoma and leptomeningeal metastases. It adjusted the price target following the 1-for-15 reverse stock split in April.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PSTV:
- Plus Therapeutics reports interim updates from two ReSPECT trials
- Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting
- Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
- Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting
- Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023